Company / Revenue
Vistagen Therapeutics, Inc. Revenue History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.1M
FY2023
5-year range
$0 / $1.3M
FY2019-FY2023
Trend
+213.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue changed +213% YoY in FY2023, a notable deviation from the 5-year average annual change of -21%.
Based on SEC 10-K filings.
$1M in FY2023 with a 5-year CAGR of -2.4%.
Improved from $0 to $1M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -2.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.4%, indicating a declining trend.
- In FY2023, revenue increased 213.3% year-over-year.
- Peak revenue was recorded in FY2011.
- Lowest revenue in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $1.1M | +213.3% |
| FY2022 | $354.0K | - |
| FY2021 | $0 | -100.0% |
| FY2018 | $1.3M | - |
| FY2017 | $0 | -100.0% |
| FY2014 | $200.4K | -85.1% |
| FY2012 | $1.3M | -35.2% |
| FY2011 | $2.1M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026